Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension
Interventions: Hula and heart health education; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions: Semaglutide Pen Injector; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Arteriosclerosis, Hypertension, Heart Diseases
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 64 Years
Timeline: Started 1995
U.S. locations: 3
States / cities: Rochester, Minnesota • Jackson, Mississippi • Rio Grande City, Texas

Conditions: Hypertension
Interventions: Walk Together, Hypertension education; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions: Glaucoma and Cataract Surgery; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intraocular Pressure, Glaucoma
Interventions: iCare HOME2 vs iCare IC200; Device
Lead sponsor: Icare Finland Oy; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Paced breathing, Active relaxation; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Cardiovascular Risk Factor
Interventions: Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: PDE5 inhibitor, Endothelin Receptor Antagonists; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 13,021 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Automated Telephone Program, Health Behavior Education; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Valsartan, Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Hypertension
Interventions: Monetary Incentives, Intrinsic Motivation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions: timolol maleate, dorzolamide/timolol maleate fixed combination; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 0 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Hyperpolarized Xe129; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hypertension Secondary to Kidney Transplant
Interventions: New Medication: Enalapril, Isradipine, Propranolol; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 5 Years to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions: L606 inhalation suspension; Combination Product
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more

Conditions: Hypertension, Pulmonary
Interventions: Blood Sample; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 907 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 12 more

Conditions: Hypertension
Interventions: Trimethaphan, Nitroglycerin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: ABPM service by Pharmacists; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Type 2 Diabetes, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: PILI 'Āina, Control; Behavioral · Other
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Honolulu, Hawaii • Kapolei, Hawaii

Conditions: Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome, Pseudoexfoliation Glaucoma
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Ola Hou i ka Hula: Hula and Hypertension

Feasibility of Semaglutide in Advanced Lung Disease

Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)

Walk Together Efficacy Trial

IOP and Medication Reduction in MIGS Procedures

iCare HOME2 Clinical Trial

Heart Inflammation and Mental Stress Study

Coordinating Pragmatic Primary Care Population Management for Obesity

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

Assessing Cosopt Switch Patients

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)

Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension

24-Hour Ambulatory Blood Pressure Monitoring in Community Pharmacies

PILI 'Āina Household

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure